Joori Park's questions to Ascendis Pharma A/S (ASND) leadership • Q2 2025
Question
Joori Park from Leerink Partners, on for Joseph Schwartz, asked what portion of the target physician base the 1,500 Yorvipath prescribers represent, and for perspective on a competitor's CNP drug having a higher AUC.
Answer
Jay Donovan Wu, EVP & President - US Market, stated the target universe is 8,000-10,000 physicians, with 3,000 considered high-priority, and they have achieved over 80% reach within that priority group. President & CEO Jan Møller Mikkelsen addressed the competitor question by emphasizing that a sustained profile without high peak concentrations (Cmax) is critical to avoid hypotension, dismissing AUC as a key metric without full profile data and expressing confidence in their combination therapy approach.